In Vitro and In Vivo Evidence that Thrombospondin-1 (TSP-1) Contributes to Stirring- and Shear-Dependent Activation of Platelet-Derived TGF-β1 by Ahamed, Jasimuddin et al.
In Vitro and In Vivo Evidence that Thrombospondin-1
(TSP-1) Contributes to Stirring- and Shear-Dependent
Activation of Platelet-Derived TGF-b1
Jasimuddin Ahamed*, Christin A. Janczak, Knut M. Wittkowski, Barry S. Coller
Laboratory of Blood and Vascular Biology, The Rockefeller University, New York, New York, United States of America
Abstract
Thrombospondin 1 (TSP-1), which is contained in platelet a-granules and released with activation, has been shown to
activate latent TGF-b1 in vitro, but its in vivo role is unclear as TSP-1-null (Thbs1
2/2) mice have a much less severe phenotype
than TGF-b1-null (Tgfb1
2/2) mice. We recently demonstrated that stirring and/or shear could activate latent TGF-b1 released
from platelets and have now studied these methods of TGF-b1 activation in samples from Thbs1
2/2 mice, which have
higher platelet counts and higher levels of total TGF-b1 in their serum than wild type mice. After either two hours of stirring
or shear, Thbs1
2/2 samples demonstrated less TGF-b1 activation (31% and 54% lower levels of active TGF-b1 in serum and
platelet releasates, respectively). TGF-b1 activation in Thbs1
2/2 mice samples was normalized by adding recombinant
human TSP-1 (rhTSP-1). Exposure of platelet releasates to shear for one hour led to near depletion of TSP-1, but this could
be prevented by preincubating samples with thiol-reactive agents. Moreover, replenishing rhTSP-1 to human platelet
releasates after one hour of stirring enhanced TGF-b1 activation. In vivo TGF-b1 activation in carotid artery thrombi was also
partially impaired in Thbs1
2/2 mice. These data indicate that TSP-1 contributes to shear-dependent TGF-b1 activation, thus
providing a potential explanation for the inconsistent in vitro data previously reported as well as for the differences in
phenotypes of Thbs1
2/2 and Tgfb1
2/2 mice.
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Introduction
Transforming growth factor b1( T G F - b1) is a multifunctional
cytokine thatplaysanimportantroleinregulatingimmuneresponse,
cell proliferation, angiogenesis, wound healing, and tissue fibrosis
[1–3]. Blood platelets contain 402100 times as much TGF-b1a s
other cells[4] and release it when activated by a variety of agents,
including thrombin[5–11]. However, virtually all TGF-b1r e l e a s e d
from plateletsis in aninactive multicomponentcomplex [large latent
complex (LLC)] in which TGF-b1 is noncovalently bound to
latency-associated peptide (LAP), which, in turn, is disulfide bonded
to latent TGF-b binding protein-1 (LTBP-1)[12,13].
In vitro studies have used multiple methods to activate latent
TGF-b1, including exposure to proteases, thrombospondin-1
(TSP-1), reactive oxygen species, and binding to integrin
receptors[7,8,10,13–26], but the mechanism of in vivo activation
remains unclear. Recently, we have shown that latent TGF-b1
released from human platelets or skin fibroblasts can be activated
through stirring or shear force[12] and that thiol-disulfide
exchange contributes to this process.
Support for a role for TSP-1 in TGF-b1 activation in vivo comes
from studies of TSP-1-null (Thbs1
2/2) mice, which demonstrate
pathological changes similar to those of TGF-b1-null (Tgfb1
2/2)
mice[27,28] although the latter have a much more severe
phenotype [29,30] usually dying within weeks after birth. To
gain additional insights into the effects of TSP-1 on TGF-b1
activation, we studied the effects of stirring and shear on latent
TGF-b1a c t i v a t i o ni nW Ta n dThbs1
2/2 mice both in vitro and in
vivo. We focused on the activation of TGF-b1 released from
platelets because TGF-b1 and TSP-1 are both highly concen-
trated in platelet a-granules and released with platelet activa-
tion[19,31–35].
Results
TSP-1-null mice have more platelets than WT mice
Mean platelet volumes (MPV) and hematologic parameters
were similar in WT and Thbs1
2/2 mice except that Thbs1
2/2
mice (n=16) had approximately 22% higher platelet counts than
WT mice (n=16; p,0.005) (Table 1).
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activation in serum
To assess whether TSP-1 contributes to stirring-dependent
activation of latent TGF-b1, serum samples were obtained from
WT and Thbs1
2/2 mice on five days. Immunoblotting confirmed
that the sera of Thbs1
2/2 mice lack TSP-1 protein (Fig. 1A). Each
sample was divided and incubated at 37uC for 2 hours with or
without stirring at 1,200 rpm.
In unstirred serum, total TGF-b1 levels were approximately
19% higher in Thbs1
2/2 mice than in WT mice (Fig. 1B)
[91615 ng/mL in WT (n=23) and 108615 ng/mL in Thbs1
2/2
mice (n=23); p,0.001]. Higher serum levels of TGF-b1i n
Thbs1
2/2 mice are consistent with their higher platelet counts
since plasma levels of TGF-b1 are only approximately 2–4 ng/mL
and nearly all of serum TGF-b1 is released from platelets during
clot formation.
Stirring of WT or Thbs1
2/2 sera for 2 hours had little impact
on total TGF-b1 levels (Fig. 1B), but increased levels of active
TGF-b1 more in WT sera than Thbs1
2/2 sera when expressed
either as absolute values or as percentages of total TGF-b1
(Fig. 1C, D) [absolute values increased from 0.5 to 2.2 ng/mL in
WT mice (n=23) and from 0.6 to 1.6 ng/mL in Thbs1
2/2 mice
(n=23; p=0.057 for interaction by ANOVA); values expressed as
percentages of total TGF-b1 increased from 0.7 to 2.3% in WT
mice (n=23) and from 0.5 to 1.6% in Thbs1
2/2 mice (n=23;
p=0.016 for interaction by ANOVA)]. The final values of active
TGF-b1 were higher in WT mouse samples than in Thbs1
2/2
samples (Fig. 1C, D)
Similar results were obtained when sera from WT and Thbs1
2/2
mice were subjected to shear for 2 hours in a cone and plate
device. The differences in final values in this smaller sample were
not statistically significant when expressed as absolute values
[active TGF-b1 was 2.260.7 ng/mL in WT mice (n=10) and
1.760.6 ng/mL in Thbs1
2/2 mice (n=10) (p=0.18 by t-test)],
but were significant when expressed as percentages of total TGF-
b1 [active TGF-b12 . 7 60.8% in WT mice (n=10) and 2.060.6%
in Thbs1
2/2 mice (n=10) (p=0.039 by t-test)]. In the combined
sample, the differences in increases between control and either
stirred or sheared sera were greater in WT (n=33) than Thbs1
2/2
mice (n=33) with respect to both absolute values (p=0.4) and
percentages of total TGF-b1 (p=0.01) (Fig. 1E, F).
TSP-1 contributes to stirring-dependent activation of
TGF-b1 in platelet releasates
Similar experiments were conducted with thrombin-stimulated
platelet releasates. Thrombin-induced platelet aggregation was
similar in WT and Thbs1
2/2 mice (Fig. 2A). Unlike in serum
samples, total TGF-b1 values in platelet releasates after thrombin
stimulation were similar in WT and Thbs1
2/2 mice [58614 ng/
mL in WT mice (n=14) and 53616 ng/mL in Thbs1
2/2 mice
(n=14)], consistent with the adjustment of the platelet counts in
the washed platelet preparations to the same level in both WT
and Thbs1
2/2 mice. As we previously observed with human
platelet releasates, total TGF-b1f r o mW Ta n dThbs1
2/2 mice
platelet releasates decreased over 2 hours of stirring by
approximately 40250%, possibly due to adsorption to the wall
of the cuvette and/or the stir bar[12]; similar decreases in total
TGF-b1 were observed with platelet releasates from Thbs1
2/2
mice (Fig. 2B). Basal levels of active TGF-b1i nt h eu n s t i r r e d
samples were also similar in WT and Thbs1
2/2 mice
[0.360.3 ng/mL in WT mice (n=14) and 0.260.2 ng/mL in
Thbs1
2/2 mice (n=14)] while post-stirring values were lower in
Thbs1
2/2 mice [absolute values: 1.160.6 ng/mL versus
2.461.5 ng/mL versus (p=0.005); percentages of total TGF-
b1: 4.062.6% versus 8.064.2% (p=0.008)]. Taken together,
stirring increased active TGF-b1 more in WT (n=14) than
Thbs1
2/2 mice (absolute values: p=0.004, percentage of total
TGF-b1: p=0.005 for interaction by ANOVA) (Fig. 2C, D). A
difference between WT and Thbs1
2/2 mice was also observed
when platelet releasates were stirred for 30 min [active TGF-b1
increased from 0.1060.015% to 4.4061.30% of total TGF-b1i n
WT versus 0.1060.010% to 2.8060.55% of total TGF-b1i n
Thbs1
2/2 mice (n=3)].
To further assess whether the defect in TGF-b1 activation by
stirring in Thbs1
2/2 mice is due to the loss of TSP-1 protein, we
tested whether purified recombinant human TSP-1 (rhTSP-1)
could correct the defect in the Thbs1
2/2 mice samples.
Preliminary immunoblot studies indicated that adding 20 mg/ml
of rhTSP-1 to platelet releasates of Thbs1
2/2 mice produced TSP-
1 levels comparable to those in platelet releasates from WT mice
and humans (Fig. 2E). Adding rhTSP-1 to unstirred platelet
releasates from both WT and Thbs1
2/2 mice did not change total
or active TGF-b1 [total TGF-b1 in control unstirred samples was
4868 ng/mL in WT mice (n=15) and 4566 ng/mL in Thbs1
2/2
mice (n=15) and after adding rhTSP-1 the values were 4866 ng/
mL in WT mice (n=4) and 4463 ng/mL in Thbs1
2/2 mice
(n=4)]. Adding rhTSP-1 to WT platelet releasates had only a
minor effect on stirring-induced activation of TGF-b1( Fig. 2F).
In sharp contrast, adding rhTSP-1 to platelet releasates from
Thbs1
2/2 mice fully corrected the defect in stirring-induced
activatibility (Fig. 2F).
Since previous studies indicated that the peptides VLAL and
LSKL can block TSP-1-mediated activation of the TGF-b1 latent
complex[36,37], we studied their effects on stirring-dependent
TGF-b1 activation. Adding either VLAL or LSKL (100 mM)
failed to inhibit stirring-induced TGF-b1 activation in human
platelet releasates when compared to a control peptide, SLLK
(stirring increased active TGF-b1 from 0.2560.05% to 5.161.9%
of total TGF-b1 in samples with SLLK, from 0.2560.04% to
5.261.6% in samples with VLAL, and from 0.1660.12% to
5.361.8% in samples with LSKL). An activating peptide KRFK
also had little or no effect on stirring-dependent TGF-b1
activation (data not shown)
Table 1. WT, wild type; Thbs1
2/2, TSP-1-null; WBC, white blood count; RBC, red blood cell count; HCT, hematocrit; MCV, mean
corpuscular volume; PLT, platelets; MPV, mean platelet volume; fL, femtoliters.
WBC (x10ˆ6
cells/mL)
Neutrophil
(% of WBC)
Lymphocyte
(% of WBC)
Monocyte
(% of WBC)
Eosinophil
(% of WBC)
RBC (x10ˆ9
cells/mL)
HCT
(%)
MCV
(fL)
PLT (x10ˆ6
cells/mL)
MPV
(fL)
WT (n=16) MEAN (SD) 6.6 (2.3) 7.5 (4.0) 84.0 (4.0) 1.6 (1.4) 4.6 (2.0) 9.7 (1.1) 47.4 (7.0) 48.0 (3.7) 1214.0 (170) 5.8 (0.8)
Thbs1-/- (n=16) MEAN (SD) 8.2 (3.7) 8.3 (4.0) 84.0 (5.4) 2.1 (1.3) 3.7 (1.7) 9.9 (0.8) 48.0 (6.4) 47.4 (4.4) 1480.0 (300)
* 5.6 (0.8)
*p,0.005 vs WT.
doi:10.1371/journal.pone.0006608.t001
Mechanism of TGF-b1 Activation
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6608Figure 1. Sera from Thbs1
2/2 mice have reduced ability to undergo activation of TGF-b1 by stirring or shear. (A) Immunoblots of WT
and Thbs1
2/2 mice sera demonstrate absence of TSP-1 in the Thbs1
2/2 mice. (B, C, D) Sera from WT (n=23) and Thbs1
2/2 (n=23) mice were stirred
(S) at 1,200 rpm or left unstirred (US) for 120 min at 37uC and then total (B) and active (C, D) TGF-b1 were measured; the latter was expressed either
as an absolute value (ng/mL) (C) or as a percentage of total TGF-b1 (D). Levels of active TGF-b1 increased less in Thbs1
2/2 than WT mice with stirring
[p=0.057 (absolute values) and p=0.016 (percentages of total TGF-b1) for interaction by ANOVA]. The post-stirring values were also higher in WT
than Thbs1
2/2 mice [p=0.19 (absolute values) and p=0.001 (percentages of total TGF-b1) by t-test]. (E, F) Sera from WT (n=10) or Thbs1
2/2 (n=10)
mice were either incubated at 37uC( 2) or subjected to shear (+) at 1,800 s
21 at 37uC for 120 min. Active TGF-b1 increased more in WT mice, both in
terms of absolute values (p=0.18 by t-test) (E) and as percentages of total TGF-b1 (p=0.039 by t-test) (F).
doi:10.1371/journal.pone.0006608.g001
Mechanism of TGF-b1 Activation
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a thiol-dependent mechanism
Since thiol-disulfide exchange contributes, at least in part, to
shear-induced TGF-b1 activation[12] we tested whether the TSP-
1-mediated contribution involves thiol-disulfide exchange. As we
previously reported, when MPB was added to human platelet
releasates before shear, it labeled a number of proteins as judged
by reaction with enzyme-linked Streptavidin (SA) SA-HRP
(Fig. 3A). The enzymatic activity intensity was markedly
diminished, however, in several regions including the one
corresponding to TGF-b1 band when MPB was added after
shear[12]. The enzymatic activity corresponding to a band that
migrated at Mr .300 kD under nonreducing conditions was
dramatically reduced after shear (Fig. 3A boxed area). To identify
the protein in the unstirred sample, it was purified with SA-
coupled beads and analyzed by SDS-PAGE. The band was
excised, subjected to trypsin digestion and analyzed by mass
spectrometry. Fourteen peptides identified by mass spectrometry
corresponded to sequences found in TSP-1 (Fig. 3B).
To assess the percentage of TSP-1 molecules that contain
accessible sulfhydryl groups, unstirred platelet releasates were
subjected to affinity chromatography on either a control-
Sepharose column or a thiol-Sepharose column. The eluates were
analyzed for the presence of proteins containing free thiols by
MPB labeling and TSP-1 by immunoblotting (Fig. 3C). Nearly all
of the thiol-reactive proteins bound to the thiol-Sepharose column
(as judged by the decrease in MPB labeling), whereas there was
little or no binding of thiol-reactive proteins to the control
Sepharose column.
We tested whether TSP-1, like TGF-b1, becomes depleted from
platelet releasates when subjected to shear. We found a time-
dependent loss of TSP-1 protein as judged by immunoblot analysis
(Fig. 3D, center panel), which could fully account for the
reduction in thiol-labeling at the expected Mr of the TSP-1 band
Figure 2. Stirring increases TGF-b1 activation in platelet releasates from WT mice more than from Thbs1
2/2 mice and recombinant
human TSP-1 corrects the defect. (A) Thrombin-induced aggregation of washed platelets from WT and Thbs1
2/2 mice. (B, C, D) Platelet
releasates were either left unstirred (US)a t3 7 uC or stirred (S) at 1,200 rpm for 120 min and then total (B) and active (C, D) TGF-b1 were measured.
(B) The decline of total TGF-b1 in stirred versus unstirred platelet releasates was similar in WT and Thbs1
2/2 mice. (C, D) Active TGF-b1 increased
more in WT than Thbs1
2/2 mice [p=0.004 (absolute values) and p=0.005 (percentages of total TGF-b1) for interaction by ANOVA]. The final values
were also higher in WT vs Thbs1
2/2 mice (p=0.005 and p=0.008 by t-test). (E) Immunoblotting of platelet releasates obtained from WT or TSP-1 null
mice demonstrated absence of TSP-1 protein in a Thbs1
2/2 mouse (lane 4); addition of 20 mg/mL of rhTSP-1 protein to the Thbs1
2/2 mouse sample
(lane 2) achieved a TSP-1 level similar to those in a WT mouse sample (lane 1) and a human platelet releasate (lane 3). (F) Adding rhTSP-1 (+) versus
BSA (2) corrected the defect in stirring-induced activation of TGF-b1i nThbs1
2/2 mice.
doi:10.1371/journal.pone.0006608.g002
Mechanism of TGF-b1 Activation
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6608Figure 3. Shear depletes TSP-1 via a thiol-dependent mechanism. (A) The proteins in human platelet releasates were labeled with MPB
(100 mM) for 30 min either before (2) or after (+) shear for 2 hours. The labeled proteins were either analyzed directly (left two lanes) or after affinity-
purification using Streptavidin-coupled beads (right two lanes). Shearing led to a dramatic decrease in intensity of the HRP reaction in select regions.
(B) One of the MPB-labeled proteins (boxed) that was most affected by shearing was identified as TSP-1 by LC-MS/MS analysis. (C) Platelet releasates
were passed through either a control-Sepharose column (Con) or a thiol-Sepharose column (Thiol) and then labeled with MPB. Depletion of thiol-
reactive proteins by the column was analyzed by reaction of the separated proteins with Streptavidin (left panel) and depletion of TSP-1 protein was
measured by immunoblotting with an anti-TSP-1 antibody (right panel). Nearly all of the proteins that labeled with MPB from the control column
were not labeled after passage through the thiol-Sepharose column. (D) Effect of increasing time of exposure to shear on depletion of TSP-1 from
platelet releasates. MPB labeling of TSP-1 was concordantly reduced with the loss to TSP-1 protein during shear as judged by reaction with
Streptavidin-HRP (left panel) and immunoblotting with an anti-TSP-1 antibody (middle panel). TGF-b1 depletion was much less pronounced as
judged by immunoblotting with an anti-TGF-b1 antibody (right panel). (E) Addition of MPB (100 mM) before shear partially prevented the loss of TSP-
1 protein as shown by immunoblotting with an anti-TSP-1 antibody. Addition of the other thiol-reactive reagents, BMCC (F) or NEM (G), similarly
protected against loss of TSP-1. Vertical lines in (F) indicate deletion of intermediate lanes from the same gel.
doi:10.1371/journal.pone.0006608.g003
Mechanism of TGF-b1 Activation
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6608(Fig. 3D, left panel). TSP-1 depletion was nearly complete within
1 hour (Fig. 3D center panel), and was greater than the partial
depletions of the Mr 25 kD TGF-b1 band (Fig. 3D, right panel)
and the major LAP (Mr 270 kD) band (data not shown). Adding
MPB before shear partially prevented the loss of TSP-1 protein
(Fig. 3E), as did the other thiol-reactive reagents BMCC (Fig. 3F)
and N-ethylmaleimide (NEM) (Fig. 3G). Densitometric quantita-
tion of TSP-1 bands from three independent experiments showed
that adding NEM before shear reduced TSP-1 protein depletion
during shear by approximately 50% (data not shown). Thus,
shear-dependent loss of TSP-1 appears to require free thiols.
Replenishing TSP-1 after stirring-induced depletion
enhances TGF-b1 activation
Since we observed both depletion of TSP-1 and a plateau of
TGF-b1 activation after 1 hour of stirring, we hypothesized that
this plateau may be due to TSP-1 depletion. To test this
hypothesis, we performed experiments in which we added either
exogenous rhTSP-1 or buffer after 1 hour of stirring and then
continued the stirring for an additional 1 hour. Adding rhTSP-1
further increased the activation of TGF-b1 by approximately 37%
compared to samples treated with buffer [from 4.8% to 7.6% of
total TGF-b1, SD=0.9% (p,0.001 by paired t-test, n=6)].
More active TGF-b1 can be recovered over time from
platelet-rich thrombi formed in vivo from WT than TSP-1-
null mice
After exposure to 20% ferric chloride (FeCl3), thrombi formed
rapidly in the carotid arteries of WT and Thbs1
2/2 mice, resulting
in complete and stable occlusion of the vessels after 5.260.9 min
in 18 of 20 WT mice and 5.560.8 min in all 18 Thbs1
2/2 mice.
The amounts of total TGF-b1 extracted in the buffer from the
thrombi contained in the arterial segments of WT and Thbs1
2/2
mice were similar when the vessels were removed 5 min after total
occlusion of the artery [5.662.4 ng/mL in WT mice (n=9) and
5.561.6 ng/mL in Thbs1
2/2 mice (n=9)]. The levels of active
TGF-b1 expressed as percentages of total TGF-b1 were higher
after 120 min than after 5 min of total occlusion in WT mice, but
not in Thbs1
2/2 mice [1.160.6% after 5 min (n=9) and
3.461.9% after 120 min (n=9) in WT mice; 1.860.9% after
5 min (n=9) and 2.061.1% after 120 min (n=9) in Thbs1
2/2
mice, p=0.0024 for interaction by ANOVA] (Fig. 4, open
circles). The concentrations of active TGF-b1 in the extracts
obtained after 120 min of occlusion were also higher in WT mice
than Thbs1
2/2 mice (p=0.041 by t-test).
When 8% FeCl3 was used instead of 20%, similar results were
obtained, but a higher percentages of thrombi were not stable
throughout the experiment. Thus, complete and stable occlusion
of the vessel occurred after 5.860.8 min in only 10 of 15 WT mice
and 7.160.8 min in only 10 of 12 Thbs1
2/2 mice. Mice that did
not form stable thrombi were excluded from the analysis. The
amounts of total TGF-b1 in the thrombi removed 5 min after total
occlusion in WT and Thbs1
2/2 mice were similar [4.062.6 ng/
mL in WT mice (n=5) and 3.962.1 ng/mL in Thbs1
2/2 mice
(n=5)]. Levels of active TGF-b1, expressed as a percentage of
total TGF-b1 were higher in extracts prepared from thrombi
obtained after 120 min of occlusion than after 5 min in WT mice,
but not in Thbs1
2/2 mice [1.761.2% after 5 min (n=5) and
2.661.7% after 120 min (n=5) in WT mice; 1.961.6% after
5 min (n=5) and 2.062.3% after 120 min (n=5) in Thbs1
2/2
mice] (Fig. 4, filled triangles).
Since the effects of 20% and 8% FeCl3 were similar (circles vs
triangles, Fig. 4), we analyzed the pooled data. Active TGF-b1,
expressed as a percentage of total TGF-b1, was higher after
120 min of occlusion than after 5 min in WT mice, but not in
Thbs1
2/2 mice (Fig. 4) [1.360.9% after 5 min and 3.161.8%
after 120 min in WT mice; 1.861.2% after 5 min and 2.061.6%
after 120 min in Thbs1
2/2 mice (p=0.0024 for interaction by
ANOVA)].
By comparing the aIIb immunoblot intensities from known
numbers of washed murine platelets to those obtained with the
lysates of thrombi, we estimated that approximately 0.6610
8
platelets are present in each carotid artery thrombus. We
previously found approximately 10 ng of total TGF-b1 per 10
8
platelets[12], which is consistent with the approximately 8 ng of
total TGF-b1 we recovered per thrombus being due to TGF-b1
release from platelets in the thrombi.
Discussion
Our data indicate that TSP-1 contributes to TGF-b1 activation
in both serum and platelet releasates under conditions of stirring
and/or shear. We found that TGF-b1 can become activated after
being released from platelets in vitro, that the activation is reduced
in the absence of TSP-1, and that full activation can be restored by
reconstitution with purified TSP-1. Moreover, we found that TSP-
1 becomes depleted from WT samples during stirring or shear,
and that replenishing TSP-1 during stirring enhances the
activation of TGF-b1. These results have implication for the role
of TSP-1 in the physiologic and pathologic mechanism(s) of
platelet-derived TGF-b1 activation and reconcile some of the
paradoxical findings that have been reported previously.
Figure 4. TSP-1 is required for in vivo time-dependent
activation of TGF-b1 in platelet-rich thrombi. Thrombosis was
induced in the carotid arteries of WT or Thbs1
2/2 mice by exposure to
either 8% FeCl3 (filled triangles, n=20) or 20% FeCl3 (open circles,
n=36) for 3 min. At either 5 min or 120 min after the vessel became
completely occluded, approximately 4 mm carotid arterial segments
were excised. The thrombi from the vessels were removed and extracts
from them were prepared for analysis of active and total TGF-b1. Since
the effects of 20% and 8% FeCl3 were similar, the data were pooled.
Active TGF-b1 levels expressed as a percentage of total TGF-b1 were
similar after 5 min. The values of active TGF-b1 increased with time after
occlusion in WT but not in Thbs1
2/2 mice (p=0.0024 for interaction by
ANOVA). Moreover, the values in the 120 min samples of WT mice were
higher than those in Thbs1
2/2 mice (p=0.041 by t-test).
doi:10.1371/journal.pone.0006608.g004
Mechanism of TGF-b1 Activation
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2/2 mice have higher numbers of platelets
than WT mice and this can account for the higher serum levels of
total TGF-b1i nThbs1
2/2 mice than WT mice. Active TGF-b1
levels before stirring or shear are lower in sera from Thbs1
2/2
mice than WT mice, suggesting that even in the absence of stirring
or shear, TSP-1 may make some contribution to TGF-b1
activation during the 4 hours of blood clotting used to prepare
serum. The absolute differences are, however, very small. Stirring
or exposure to shear forces accentuates the difference in TGF-b1
activation, with higher levels of active TGF-b1 being produced in
WT than Thbs1
2/2 mice, whether expressed as an absolute value
or as a percentage of total TGF-b1. Stirring or shear does,
however, increase the level of active TGF-b1 in the serum of
Thbs1
2/2mice, demonstrating that activation is not entirely TSP-1
dependent. Similar data were obtained when platelet releasates
from the two groups of mice were stirred, although the absolute
values differed. Most importantly, the addition of rhTSP-1 to the
Thbs1
2/2mice samples fully corrected the defect in TGF-b1
activatability, providing strong support for the interpretation that
the differences we observed with sera and platelet releasates are
unlikely to be due to differences in proteins other than TSP-1.
Several observations support a biological role for TSP-1 in the
activation of TGF-b1. Thus, in vitro studies have demonstrated that
purified TSP-1 can activate TGF-b1 and the sites of interaction
between the molecules have been localized to the K
412RFK
415
sequence between the first and second type 1 repeats of TSP-1 and
the L
54SKL
57 sequence in LAP[38]. Moreover, there is evidence
of an intimate association between the two molecules since TGF-
b1 copurifies with TSP-1 and purified radiolabeled TGF-b1 can
bind to TSP-1, presumably by interacting with the WSXW
sequence in the type-1 repeats[19,20,22–24,38]. Most importantly,
although one must be cautious in making judgments about the
importance of a protein based on the phenotype of gene targeted
animals, the similarity in organ damage in Tgfb1
2/2mice and
Thbs1
2/2 mice provides support for an in vivo role for TSP-1 in
TGF-b1 activation, especially since treating the Thbs1
2/2 mice
with the KRFK peptide, partially rescued the pathological changes
in the lungs and pancreas of Tgfb1
2/2mice[27]. In addition,
Thbs1
2/2 mice subjected to coronary occlusion and reperfusion
show enhanced myocardial inflammation and adverse myocardial
remodeling in association with a trend towards reduced TGF-b1
signaling relative to WT mice[39]. A role for TSP-1 in TGF-b1
activation may have particular significance for platelet biology
since platelets contain high concentration of both TSP-1 and
TGF-b1 and release both in response to thrombin[19,20,31–35].
On the other hand, the much greater severity of the phenotype
of the Tgfb1
2/2mice than the Thbs1
2/2 mice makes it clear that a
mechanism(s) of TGF-b1 activation that does not require TSP-1
must exist in vivo. In addition, Grainger and Frow could not
activate TGF-b1 contained in latent complexes with platelet-
derived purified TSP-1[40], and Abdelouahed et al. found no
evidence for TSP-1 activating TGF-b1 released from platelets,
with both WT and Thbs1
2/2 mice having similar levels of active
TGF-b1[5]. A number of technical differences in the design of the
experiments we conducted and those conducted by these
investigators can perhaps reconcile the apparent discrepancies in
our results. Thus, Grainger and Frow appear to have incubated
their reagents without stirring and Abdelouahed et al. added
thrombin to washed platelets and stirred for only 3 min before
assaying the supernatant. In contrast, we stirred samples (serum or
platelet releasates) for 2 hours because our previous studies
demonstrated that stirring- or shear-induced TGF-b1 activation
is time-dependent and requires more than 1 hour to reach its
plateau.
Since it has been reported that the TGF-b1 complex peptides
VLAL and LSKL can inhibit TSP-1-mediated activation of TGF-
b1 in some systems[36,37], we tested the effects of these peptides on
stirring-induced activation of TGF-b1 in platelet releasates. These
peptideshadlittle ornoeffectonTGF-b1 activation,suggesting that
shear- and/or stirring-induced activation may involve interactions
mediated by other regions of the TGF-b1 complex.
Our data indicate that under conditions of optimal stirring and
shear, the presence of TSP-1 at levels found in serum and platelet
releasates enhances TGF-b1 activation. The TSP-1 contribution
in serum increases active TGF-b1 by approximately 0.5–1.0 ng/
mL, which is consistent with a biologically important role, since
this concentration is approximately 50- to 100-fold more than the
minimum concentration required to induce transcription of the
TGF-b1-responsive gene plasminogen activator inhibitor-1 (PAI-
1)[41].
It is of interest to consider why the TSP-1 contribution to
activation of TGF-b1 is limited to only approximately 1% of total
serum TGF-b1. It has been suggested that post-translational
modifications of one or both molecules may be required for
complex formation[5]. Our data can be interpreted to suggest two
additional hypotheses. The first is that only a subpopulationof TSP-
1 molecules in the correct conformation(s) (regardless of post-
translational modifications)can participate in the activation process.
In fact, it has been demonstrated that TSP-1 adopts markedly
different conformations, depending on the temperature, pH, cation
concentrations, and degree of purification[42–45]. Support for this
hypothesis comes from evidence that the conformation of TSP-1
affects its efficiency in mediating thiol-disulfide exchange with other
molecules[42–44,46]. We previously found that thiol-disulfide
exchange contributes partially to the stirring- and shear-induced
TGF-b1 activation mechanism and in this study we demonstrated
that TSP-1 is a shear-sensitive protein and that freethiols contribute
to the changes that TSP-1 undergoes when subjected to shear force.
Moreover, shear has been found to facilitate thiol-disulfide
exchange reactions in a number of systems, including modification
of von Willebrand factor (vWf), one of the proteins demonstrated to
undergothiol-disulfideexchangeinthepresenceofTSP-1[47,48].It
is therefore possible that TSP-1-mediated TGF-b1 activation also
requires thiol-disulfide exchange. The second hypothesis is that
TSP-1 depletion limits the contribution of TSP-1 to TGF-b1
activation. This would provide a negative feedback control
mechanism to prevent excessive TGF-b1 activation unless there
was an ongoing supply of TSP-1 as may occur if there is continued
release of TSP-1 from additional platelets. In fact, we found that
replenishingTSP-1duringstirringresults in a furtherincrease inthe
TGF-b1 activation. These hypotheses are not mutually exclusive
and thus multiple mechanisms may contribute to the observed
phenomenon.
Our data may also bear on the interesting question of how high
concentrations of both TGF-b1 and TSP-1 can be stored in platelet
a-granule without inducing activation of TGF-b1. It has previously
been hypothesized that an inhibitory molecule in a-granules may
limit the activation of TGF-b1 by TSP-1[5]. Our finding that TSP-
1 mediated activation requires stirring or shear provides an
alternative explanation, as well as a mechanism by which TGF-
b1 released from platelets along with TSP-1 can be activated by the
shear forces in the circulation. In addition, if thiol-disulfide
exchange is required for activation, the relatively low pH in a-
granules[49]maylimitactivation becausethiol-disulfide exchangeis
favored at higher than neutral pH where there is a higher ratio of
protonated thiol than deprotonated thiolate group[12,50].
In conclusion, TSP-1 contributes to stirring- and shear-induced
TGF-b1 activation in vitro and to TGF-b1 activation over time in
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the presence of a mild Tgfb1
2/2-like phenotype in Thbs1
2/2 mice.
Our data also provide evidence that free thiols in TSP-1 affects its
ability to undergo stirring- and shear-dependent changes, raising
the possibility that TSP-1’s contribution to shear-dependent TGF-
b1 activation might be mediated by a thiol-disulfide exchange
mechanism. Our data can also provide a novel mechanism for
negative feedback control of TGF-b1 activation via depletion of
TSP-1 and may reconcile many of the apparently inconsistent
observations that have previously been made about the role of
TSP-1 in TGF-b1 activation both in vitro and in vivo.
Materials and Methods
Antibodies and Reagents
A murine monoclonal antibody (mAb) to TSP-1 (Ab-11) was
obtained from NeoMarkers (Fremont, CA), a chicken polyclonal
IgY antibody to human TGF-b1 and recombinant human TSP-1
(rhTSP-1) were obtained from R&D Systems (Minneapolis, MN),
TSP-1 inhibitor and control peptides were obtained from Ana Spec
Inc.(SanJose,CA),andStreptavidincoupledtomagneticbeadswas
obtained from Invitrogen (Carlsbad, CA). All other reagents and
antibodies were from the same sources previously reported[12].
TGF-b1 Assays
Both immunologic (ELISA) and functional (mink lung epithelial
cell; MLEC) assays were used to measure active TGF-b1 before
and after treating the samples with 0.2 volume of 1N HCl for
20 min at room temperature to convert latent TGF-b1 to active
TGF-b1 as described previously[12].
Mouse Experiments
Mice. A total of 113 wild-type (WT) and 113 TSP-1-null mice
(Thbs1
2/2) on a C57Bl/6 background were obtained from Jackson
Laboratory (Bar Harbor, ME). Mice were housed in a controlled
environment (2362uC; 12 hr light/dark cycles), and fed a
standard diet (5001, Purina Mills; Richmond, IN). All
experimental procedures conformed to the recommendations of
the Guide for the Care and Use of Laboratory Animals (National
Research Council, Washington D.C: National Academy Press;
1996. NIH publication no. 78-23), and approved by The
Rockefeller University Animal Care and Use Committee. All
mouse experiments were done blindly.
Hematological data
Hematological parameters were analyzed on EDTA-anticoag-
ulated blood from 16 WT and 16 Thbs1
2/2 mice within 30–
60 min after blood collection using an automated dual angle light
scatter instrument (ADVIA120, Bayer Diagnostics, Tarrytown,
NY) as described previously[51]
Latent TGF-b1 activation in mouse platelet releasates,
serum and plasma
In an attempt to simulate in vivo platelet deposition, aggregation,
and secretion, followed by exposure of the releasate to systemic
shear force, WT and Thbs1
2/2 mouse releasates were prepared
from washed platelets treated with thrombin (0.125 U/mL) without
stirring for 5 min at 37uC and then the releasates were subjected to
either stirring or shear as described previously[12]. We also
analyzed mouse serum prepared as previously described[12], to
simulate situations in which in vivo thrombin generation results in
coagulation. For mouse plasma, blood was drawn percutaneously
usinganultrasound-guided left-ventricular punctureandplacedina
polypropylene tube containing 0.1 volume of 0.1 M trisodium
citrate. Plasma was collected after centrifuging the sample at
3,0006g for 15 min at 4uC immediately after blood collection.
Samples of platelet releasates, serum, and plasma (1502200 mL)
were incubated at 37uC with stirring in a glass cuvette (7650 mm)
containing a metal stir bar (165 mm) for 2 hours in an
aggregometer (Kowa Optimed Inc, Tokyo, Japan) or subjected
to a shear rate of 1,800 s
21 in a cone and plate device (ImpactR;
DiaMed Inc. Miami, FL) at 37uC for the indicated time periods.
Active TGF-b1 was measured before and after acidification of
samples (to convert latent TGF-b1 to active TGF-b1) using the
ELISA and/or MLEC assays. For the stirring experiments,
14 WT and 14 Thbs1
2/2 mice were used to prepare platelet
releasates, 15 WT and 15 Thbs1
2/2 mice were used for rhTSP-1
reconstitution assay, 23 WT and 23 Thbs1
2/2 mice were used to
prepare serum samples, and 7 WT and 7 Thbs1
2/2 mice were
used to prepare plasma. For shearing experiment, serum samples
from 10 WT and 10 Thbs1
2/2 mice were tested.
Labeling of Free Thiols
Proteins containing free thiols in human platelet releasates were
labeled with 3-(N-maleimidylpropionyl) biocytin (MPB) as de-
scribed previously[12,52]. Briefly, MPB (100 mM final concentra-
tion) was added to platelet releasates and the samples were either
stirred at 1200 rpm or subjected to a shear rate of 1800 s
21 for the
indicated time periods at 37uC. Residual unreacted MPB was
quenched by adding reduced glutathione (GSH; 200 mM). In
some studies, MPB-labeled proteins were incubated with Strepta-
vidin-coated magnetic beads (Dynabeads, Invitrogen) to isolate the
MPB-labeled proteins. The beads were washed and then
resuspended in Tris-glycine SDS sample buffer (Invitrogen) to
release the proteins from the beads; the solution was heated to
100uC for 3 min and electrophoresed in 8216% gradient Tris-
glycine gels (Invitrogen). After transfer of proteins to polyvinyli-
dene fluoride (PVDF) membranes, biotinylated proteins were
detected with streptavidin-horse radish peroxidase (HRP) using
chemiluminescence (ECL detection system, Amersham; Pitts-
burgh, PA). TSP-1 was detected with anti-TSP-1 mAb (Ab-11).
Appropriate secondary antibodies conjugated to horse radish
peroxidase (HRP) (Jackson Laboratories; West Grove, PA) were
used to detect bound antibodies by chemiluminescence. Band
intensities were quantitated using image analysis software (NIH-
Scion Image; Scion Corporation; Frederick, MD).
Mass spectrometic analysis
MPB-labeled proteins were incubated with Streptavidin-coated
magnetic beads (Dynabeads, Invitrogen) to isolate the MPB-
labeled proteins. The beads were washed and then resuspended in
Tris-glycine SDS sample buffer (Invitrogen, Carlsbad, CA) to
release the proteins from the beads; the solution was heated to
100uC for 3 min and electrophoresed in 8–16% gradient Tris-
glycine gels. The gel band at Mr approximately 450 kD was
excised, diced, and treated with 10 mM DTT in 0.1 M
ammonium bicarbonate to reduce disulfide bonds. Free cysteine
residues were alkylated with freshly made 55 mM iodoacetic acid
in 0.1 M ammonium bicarbonate. Tryptic digestion [25 ng/mlo f
sequence grade-modified trypsin (Promega) in ammonium bicar-
bonate buffer] was conducted for at least 16 h at 30uC. The
resultant tryptic peptide mixture was separated by gradient elution
with a nano-HPLC system (Dionex, Sunnyvale, CA) interfaced
with a LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientific Inc). The MS/MS spectra were analyzed with
MASCOT search engine to identify proteins from primary
sequence databases.
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thrombosis model
Mice(28 WTand28 Thbs1
2/2) were anesthetized with isoflurane
and maintained under inhalation anesthesia as previously de-
scribed[53]. Mouse body temperature was monitored with a rectal
probe and thermistor (THM100; Indus Industries, Houston, TX)
a n dm a i n t a i n e da t3 7 62uC with a temperature-controlled heating
pad (THM100). The left common carotid artery was dissected and a
Dopplerflow probe(Transonics0.5;TransonicSystems,Ithaca,NY)
was placed on the carotid artery proximal to the bifurcation as
previously described[54]. Thrombosis was induced by placing a
163 mm piece of filter paper (Whatman no. 1; Maidstone, UK)
saturated with either 8 or 20% FeCl3 on the exposed segment of the
carotid arteryfor3 min. Occlusivethrombiformeduniformlywithin
approximately 5 min after exposure to FeCl3 and after an additional
5 or 120 min, approximately 4 mm arterial segments containing the
thrombi were excised. The segments were then opened, and the
thrombi were removed and dispersed in 150 mL of HBMT buffer,
pH 7.4 on ice for 1 hour. After centrifugation at 14,0006gf o r
20 min at 4uC, the carotid extracts were saved and the pellets were
lysed with 150 mL of buffer containing 1% Triton X-100 for 1 hour
at 4uC and diluted with 150 mL of HBMT buffer, pH 7.4. Lysates
were collected after centrifugation at 14,0006g for 20 min at 4uC.
Total TGF-b1 in the extracts and lysates were measured by ELISA.
Active and total TGF-b1 in the extracts from the carotid artery
thrombi were also measured by the more sensitive MLEC biological
assay. To make sure that only TGF-b1 activity was being measured
inthisassay,samplesweremeasured inthe presenceorabsenceofan
anti-TGF-b1 neutralizing antibody (R&D Systems) and only the
neutralizableactivitywasreported.Wefoundthat50280%ofactive
TGF-b1 was inhibited by the anti-TGF-b1 neutralizing antibody.
To estimate the numbers of platelets contained in the thrombi,
carotid lysates were immunobloted for aIIb using a goat anti-aIIb
goat polyclonal antibody (SantaCruz Biotechnology, CA) and
compared with lysates prepared from known numbers of washed
murine platelets. In preliminary experiment, we assessed whether
FeCl3 (100 mM) could directly activate TGF-b1 in WT platelet
releasate samples and found only a minimal increase in active TGF-
b1( a c t i v eT G F - b1 increased from 0.24% to 0.30% of total TGF-b1
after 2 hours of incubation at 37uC).
Statistical Analysis
Ranges are given as mean6SD. S-PLUS 8.0 (www.insightful.
com, Seattle, WA) was used for graphics and analysis. A mixed
model with conditions (stirring/shearing versus unstirred/un-
sheared, or 5 min versus 120 min, respectively) and mouse strain
(WT versus Thbs1
2/2) as fixed factors and date of experiments
and animal within date of experiment as nested random factors
were used for ANOVA. The condition versus strain interaction
was tested to assess differences in responses between strains. Since
combining experiments into a single analysis when different
interventions have similar effects increases sample size and, thus,
power, whereas combining them when the interventions have
different effects increases the within-group variance and, thus,
avoids the risk of reporting false positive results. Hence, we
conservatively combined data obtained under similar condition
(stirring and shear, complete occlusion obtained under different
concentrations of clotting agents) by adding an additional (fixed)
stratification factor to the ANOVA model, where appropriate.
Comparisons between WT and Thbs1
2/2 mice for individual time
points across experimental conditions (date of experiment) by
means of Student’s t-test for independent samples were also
included, with the recognition that this analysis does not reflect
baseline conditions and environmental confounders.
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